Schedule 13G ownership disclosure

KalVista Pharmaceuticals Inc

Common Stock, par value $0.001 per share · CUSIP: 483497103

Event date: 2026-01-05

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Point72 Asset Management, L.P.

    Shares: 2,781,902.00 · Class: 5.5%

  • Point72 Capital Advisors, Inc.

    Shares: 2,781,902.00 · Class: 5.5%

  • Steven A. Cohen

    Shares: 2,781,902.00 · Class: 5.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-26-000191
Form type
SCHEDULE 13G/A
Filer
KalVista Pharmaceuticals, Inc.
CIK
CIK 1348911
Filed
Jan 13, 2026
Reporting period
Jan 05, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub